Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced

AIMS: Empagliflozin improves cardiovascular and renal outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but its efficacy and safety across patient's age is not well established. METHODS AND RESULTS: We assessed the effects of empagliflozin (10 mg daily) versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Anker, Stefan D., Butler, Javed, Farmakis, Dimitrios, Ferreira, João Pedro, Gollop, Nicholas D., Brueckmann, Martina, Iwata, Tomoko, Pocock, Stuart, Zannad, Faiez, Packer, Milton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Sglt2 Inhibitors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092219/
https://www.ncbi.nlm.nih.gov/pubmed/36194680
http://dx.doi.org/10.1002/ejhf.2707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092219/
https://www.ncbi.nlm.nih.gov/pubmed/36194680
http://dx.doi.org/10.1002/ejhf.2707

Ejemplares similares